Olmesartan Medoxomil + Amlodipine + HydrochlorothiazideThird Party Manufacturing in India

Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide work by combining three powerful mechanisms to control severe blood pressure.

Olmesartan acts by selectively blocking the binding of angiotensin II to the AT1 receptor, causing vascular smooth muscle relaxation and vasodilation. Amlodipine, a calcium channel blocker, prevents calcium ions from entering vascular smooth muscle and cardiac muscle cells, further dilating peripheral arteries and reducing peripheral vascular resistance. Finally, hydrochlorothiazide is a thiazide diuretic that reduces blood volume by increasing the excretion of sodium and water in the kidneys.

Unlike monotherapy treatments, this triple combination delivers a synergistic effect to aggressively lower blood pressure from multiple physiological angles. It is highly effective for patients whose hypertension remains uncontrolled on dual therapy regimens.

Therapeutic Uses

Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide are prescribed for the treatment of:

• Essential Hypertension: Specifically formulated for patients whose blood pressure is not adequately controlled on a dual combination of these agents.
• Cardiovascular Risk Reduction: Lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions, by maintaining optimal blood pressure control.

Why Manufacturers Choose This Triple Combination

This complex formulation is highly valued in the Indian pharmaceutical manufacturing sector due to the increasing prevalence of resistant hypertension. The demand for triple fixed-dose combinations is growing rapidly in both domestic PCD franchises and export markets.

Manufacturing this formulation requires precise blending and stability control, making it a premium offering for third party manufacturing in India. Our WHO-GMP certified facilities ensure consistent quality and exact dosage alignment for this critical cardiovascular medication.